from CARMAT (EPA:ALCAR)
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
French joint-stock corporation (société anonyme) with share capital of €1,398,139.72 €
Registered office: 36, avenue de l’Europe
Immeuble l’Etendard Energy III
78140 Vélizy Villacoublay, France
Registered in the Versailles Trade and Companies Register under no. 504 937 905
2024 INTERIM FINANCIAL REPORT
SIX MONTHS ENDED JUNE 30, 2024
THIS IS A FREE TRANSLATION INTO ENGLISH OF 2024 INTERIM FINANCIAL REPORT (‘RAPPORT FINANCIER SEMESTRIEL 2024’) PUBLISHED IN FRENCH ON SEPTEMBER 06,2024.
THIS TRANSLATION IS PROVIDED SOLELY FOR THE CONVINIENCE OF ENGLISH-SPEAKING READERS.
THE 2024 INTERIM FINANCIAL REPORT (‘RAPPORT FINANCIER SEMESTRIEL 2024’) IS AVAILABLE ON THE COMPANY’S WEBSITE.
1
CONTENTS
1 DECLARATION BY THE PERSON RESPONSIBLE FOR THE
4 NOTES TO THE 2024 INTERIM FINANCIAL STATEMENTS............................................ 12
1 DECLARATION BY THE PERSON RESPONSIBLE FOR THE INTERIM
FINANCIAL REPORT AT JUNE 30, 2024
I hereby declare that, to the best of my knowledge, the financial statements presented for the six months ended June 30, 2024 were prepared in accordance with applicable accounting standards, and give a true and fair view of the assets, liabilities, financial position and results of the Company, and that the interim review of operations on pages 4 to 7 presents a true and fair view of the significant events that took place during the first half of the year, their impact on the financial statements and the main transactions between related parties, along with a description of the principal risks and uncertainties for the remaining six months of the year.
Stéphane Piat
Chief Executive Officer, CARMAT
2 REVIEW OF OPERATIONS
2.1 SUMMARY OF THE INTERIM FINANCIAL STATEMENTS AT JUNE 30, 2024
Income statement | 6 months | 12 months | 6 months |
(in millions of euros) | ended June 30, 2024 | ended Dec. 31, 2023 | ended June 30, 2023 |
Revenue | 3.3 | 2.8 | 0.6 |
Net operating expense | (25.4) | (52.5) | (25.9) |
Net financial expense | (1.7) | (3.1) | (1.7) |
Net non-recurring income | 0.1 | 0.0 | 0.0 |
Research and innovation tax credit | 0.8 | 1.7 | 1.0 |
Net loss | (26.2) | (53.9) | (26.7) |
Balance sheet (in millions of euros) |
June 30, 2024 |
Dec. 31, 2023 |
June 30, 2023 |
Total assets | 54.2 | 53.1 | 64.5 |
Total equity | (39.4) | (43.8) | (24.5) |
(Net cash)/Net debt* | 47.1 | 49.6 | 32.7 |
Cash flow statement | 6 months | 12 months | 6 months |
(in millions of euros) | ended June 30, 2024 | ended Dec. 31, 2023 | ended June 30, 2023 |
Cash and cash equivalents at beginning of period | 8.0 | 51.4 | 51.4 |
Net cash used in operating activities | (25.7) | (53.5) | (30.7) |
Net cash used in investing activities | (1.1) | (4.9) | (1.6) |
Net cash from financing activities | 30.3 | 15.0 | 4.7 |
Cash and cash equivalents at end of period | 11.4 | 8.0 | 23.8 |
* Long-term financial liabilities plus short-term financial liabilities less cash and cash equivalents.
First-half 2024 earnings
CARMAT generated €3.3 million in revenue in the first half of 2024, corresponding to the sale of seven artificial hearts for commercial implants (in Germany, Italy and Poland) and 13 as part of the EFICAS clinical study in France.
In the first six months of the year, CARMAT’s efforts and resources were predominantly focused on:
- deploying and developing its business in Europe;
- stepping up its EFICAS clinical study in France;
- continuing discussions with the FDA with a view to starting up the second cohort of its EFS (early feasibility study) in the United States;
- strengthening its financial structure.
The Company continued to keep tight control over its operating expenses, enabling it to slightly reduce its net operating expense to €25.4 million in the first half of 2024 from €25.9 million in first-half 2023.
After taking into account net financial expense of €1.7 million and €0.8 million in income from the research tax credit, CARMAT ended the first half of 2024 with a net loss of €26.2 million (compared with a €26.7 million net loss in the first six months of 2023).
Sales
The €3.3 million in revenue recorded by CARMAT in the first half of 2024[1] means that it has already exceeded its full-year revenue for 2023 (€2.8 million). The first-half 2024 revenue figure corresponds to the sale of 20 Aeson® hearts for implants performed during the period, compared with three in the first half of 2023. The rate of implants increased to four Aeson® hearts per month in the second quarter of 2024 (generating revenue of €2.2 million), compared with two hearts per month in the first quarter (representing €1.1 million in revenue).
Cash flows and financial structure
Cash and financing
At June 30, 2024, the Company had €11.4 million in cash and cash equivalents, versus €8.0 million at December 31, 2023.
Cash flows from operating and investing activities represented a net cash outflow of €26.8 million, representing an improvement of more than €5 million compared with the €32.2 million net outflow recorded for the first half of 2023, mainly reflecting tight control over operating expenses and capex. In the first half of 2024, the Company obtained the following funds:
- an aggregate €32.5 million in proceeds from two capital increases (€16.5 million in January and €16.0 million in May); and
- €0.3 million corresponding to the final tranche of the total €1.4 million “CAP23” grant awarded to CARMAT as a winner of the French government’s “Industrial Recovery Plan – Strategic Sectors” call for projects.
In addition, on July 5, 2024, i.e., after the half-year close, the Company set up a flexible equity financing line with Vester Finance[2], involving the issue of up to 3,500,000 shares (corresponding to c. €8.2 million based on CARMAT’s share price of €2.345 on June 30, 2024) over a 24-month period, with CARMAT immediately receiving €2.2 million.
In view of all of these factors[3], and based on its current business plan, CARMAT’s confirmed financial resources should enable it to fund its business until end-September 2024. The Company is actively working on various financing options to secure the financial resources it requires to continue as a going concern beyond that date[4]. The Company estimates its financing requirements over the next 12 months to be c. €45 million.
Net debt
On March 22, 2024, the Company reached an agreement with all of its lenders – the European Investment Bank (EIB), BNP Paribas (BNPP) and Bpifrance (BPI) – on new repayment terms for its bank loans[5], including, in particular, an extension of at least two years of the final maturity of each of the loans, and equitization[6] of the loan taken out with the EIB, whose term commenced on June 13, 2024.
Taking into account this agreement, CARMAT’s net debt at June 30, 2024 was €47.1 million, breaking down as follows:
(Net cash)/Net debt (in thousands of euros) | June 30, 2024 |
Long-term financial liabilities (>12 months) | 57,339 |
Short-term financial liabilities (<12 months) | 1,158 |
Total financial liabilities [a] | 58,497 |
Cash and cash equivalents [b] | 11,420 |
(Net cash)/Net debt [a-b] | 47,077 |
Short-term financial liabilities comprise:
- €0.2 million in interest due on tranches 2 and 3 of the EIB loan; and
- an aggregate €1.0 million in principal and interest payments due on the government-guaranteed loans (“PGEs”) taken out with BNPP and BPI.
2.2 SIGNIFICANT EVENTS OF FIRST-HALF 2024 AND RECENT DEVELOPMENTS
2.2.1 MARKED ACCELERATION IN SALES
Twenty Aeson® implants were performed in the first half of 2024, versus three in the first half of 2023. The rate of Aeson® implants reached four per month in the second quarter, doubling from two hearts per month in the first quarter.
In the first six months of 2024, CARMAT generated €3.3 million in revenue, which means that it has already exceeded its full-year revenue for 2023 (€2.8 million).
Sales were generated for the first time in Poland, bringing the number of countries in which CARMAT has a commercial activity to three (Germany, Italy and Poland). A total of nine hospitals carried out their first Aeson® implants in the first half of 2024 – four in Germany, three in France and two in Poland.
This very positive trend reflects the encouraging take-up of CARMAT’s artificial heart therapy in Europe.
2.2.2 VERY GOOD MOMENTUM FOR THE EFICAS CLINICAL STUDY
In the first six months of 2024, 13 Aeson® implants were performed as part of the EFICAS clinical study in France, corresponding to a rate of more than two implants per month.
This brings the total number of Aeson® implants performed under this study to 24 at June 30, 2024, paving the way for the imminent completion of half of the target number of patient recruitments, which represents 52 patients in total.
At June 30, all of the French centers taking part in the study – a total of 10[7] – had already referred patients, and nine of them had performed at least one implant. The hospitals of Lille and Lyon, and the Hôpital Européen Georges Pompidou (HEGP) in Paris had each already carried out five implants, which clearly illustrates healthcare professionals’ high level of satisfaction with CARMAT’s total artificial heart therapy as they become familiar with Aeson® and identifying eligible patients.
CARMAT expects to publish the results of the EFICAS clinical study in the last quarter of 2025, which it believes will lead to a strong and sustained acceleration in the take-up of Aeson® artificial hearts in Europe.
EFICAS is also a key study both for securing social security reimbursement of Aeson® in France and for supporting CARMAT’s application for Premarket Approval (PMA) (marketing authorization in the United States issued by the FDA – Food & Drug Administration), which the Company expects to receive in 2027.
2.2.3 CONTINUED BUSINESS DEVELOPMENT
Europe (and Middle East)
In the first half of 2024, CARMAT trained nine new hospitals to perform Aeson® commercial implants, expanding its network to 42 centers in 14 different countries[8]. The Company is therefore well on track to meet its target of 50 trained hospitals by the end of 2024.
Out of these 42 centers, three-quarters were active in first-half 2024, i.e., they had already submitted patient files to CARMAT to assess their eligibility for implantation.
In addition, six countries (Switzerland, Austria, Slovenia, Croatia, Greece and Israel) were activated and therefore ready to perform implants. The Company plans to activate more countries in Europe in the second half of the year.
United States
Discussions with the FDA (the U.S. Food & Drug Administration) continued during the period, with a view to commencing the second cohort of seven patients in the EFS[9] (early feasibility study). Based on all of the information available to the Company, CARMAT expects this to happen in early 2025, and still foresees the commercial launch of Aeson® in the United States taking place during the second half of 2027.
2.2.4 PRODUCTION RAMP-UP
Thanks to its expanded production capacity, with a second production facility coming on stream at its Bois d'Arcy site at the end of 2023, as well as its growing supplier base and the experience it has built up over the last few years, the Company had a continuous production output in the first half of 2024, enabling it to meet demand without any difficulties, while keeping up an inventory level of more than 20 Aeson® hearts.
CARMAT intends to continue to implement its industrial roadmap aimed at continuously improving its production processes, securing its supplies, gradually reducing the production cost for its artificial heart, and aligning its capacity development with demand.
2.2.5 STRENGTHENING THE COMPANY'S FINANCIAL STRUCTURE
Debt restructuring
In March 2024, CARMAT reached an agreement with all of its lenders (the EIB, BNPP and BPI) on new repayment terms for its bank loans. In particular, the agreement provides for the final maturity of each of the loans to be extended by between 24 and 30 months, and for the equitization of the EIB loan[10].
This debt restructuring provides the Company with the certitude of reducing its loan repayments by more than €30 million between 2024 and 2025[11] and it also means that CARMAT can expect to see a significant reduction in its cash repayments between 2026 and 2028 as a result of the equitization process (which began on June 13, 2024 for the first tranche of the loan).
Capital increases
The Company also carried out two capital increases in the first half of 2024 – one in January and the other in May – which generated gross proceeds of €16.5 million and €16.0 million respectively. CARMAT’s major shareholders, Sante Holdings and Lohas/Les Bastidons (Pierre Bastid), took up a significant number of the shares issued, demonstrating their strong support of the Company.
2.2.6 CHANGES IN THE COMPANY’S GOVERNANCE
On June 24, 2024, Pierre Bastid was appointed as Chairman of the Board of Directors, replacing Alexandre Conroy, who resigned for personal reasons.
A seasoned industrialist and entrepreneur, Pierre Bastid knows CARMAT very well, having served on its Board as a director since 2018. He is also one of the Company's main shareholders via the Lohas and Les Bastidons entities, which he controls, and which together hold 13.1%[12] of CARMAT’s share capital. Since taking a stake in CARMAT back in 2016, Pierre Bastid has subscribed for shares in each of the capital increases carried out by the Company.
On the same date, André Muller, an independent director, resigned from CARMAT’s Board of Directors following his appointment as Chief Executive Officer of Idorsia.
Following these changes, CARMAT’s Board is now chaired by Pierre Bastid and has 10 members, including five independent directors.
2.2.7 NEXT STEPS
2024 Objectives
For the second half of 2024, the Company forecasts a sales trend which would reach a yearly turnover within a range of €8 million to €12 million, to be compared with revenue of around €14 million initially planned. This forecast reflects a better understanding of the market access dynamics and seasonality, as well as two summer months during which the level of surgical activity remained limited across Europe.
Regarding the other key objectives for 2024, the Company confirms it is on track to achieve them by the end of the year, namely:
- a patient recruitment rate of around 75% in the EFICAS clinical study,
- c. fifty centers trained for commercial implants,
- a c. 20% reduction in cash burn (operations and investments) vs 2023, - filing to resume the EFS study (United States).
Key catalysts anticipated in 2025 to support short and medium-term development
In 2025, the Company anticipates four key drivers to support its short and medium-term development:
- Q1 2025: initiation of the second cohort of patients in the EFS study in the United States,
- H1 2025: publication in a scientific journal of the Aeson® clinical results for patients previously under "ECLS"[13],
- H2 2025: resumption of the PIVOTAL study in Europe for a cohort of patients not eligible for heart transplant, to target the "Destination Therapy" indication,
- Q4 2025: publication of the results of the EFICAS study (52 patients).
In the short term, continued development in Europe supported by scientific publications
With over 70 patients having received an implant since Aeson® was created, CARMAT has built up substantial clinical experience. This testifies to the technology's unique performance and safety profile, particularly given that the Company tends to treat patients at an increasingly severe stage of the disease.
In the coming months, the Company intends to carry-on with the gradual spread of its therapy across Europe, in the bridge-to-transplant indication for which Aeson® is currently approved, by building on this clinical experience, but also on the growing reputation of Aeson® , supported in particular by a ripple effect between centers, and spontaneous positive communication by physicians and hospitals performing implants.
Aeson® sales' growth should then accelerate significantly following the publication of Aeson® clinical results in patients previously under ECLS, anticipated in Q1 2025, and EFICAS study results in Q4 2025.
In the medium term, heading towards the US market and the Destination Therapy
In the medium term, the Company continues to target access to the US market, as well as the Destination Therapy (DT) indication (or so called "permanent implant"), which would allow patients to remain under Aeson® support with no subsequent heart transplant. In terms of addressable market, the Destination Therapy represents one of the biggest opportunities in cardiology.
The anticipated launch, in Q1 2025, of the second cohort of patients in the US EFS study, and the expected resumption in H2 2025 of the European PIVOTAL study with a cohort of patients not eligible for heart transplant, are important milestones to ultimately get Aeson® approved for this strategic indication.
2.3 MAIN RISK FACTORS
Risk factors are discussed in detail in Chapter 2 of the 2023 Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) under number D. 24-0374. Regarding the risk of « Significant shareholding dilution », the Company now considers it as « critical » (and no longer as « major », as previously reported in Chapter 2 of the 2023 Universal Registration Document), as its potential impact is now assessed as « major » and its likelihood as « very high ».
To date, the Company is not aware of any other significant changes in these risk factors.
The Company would also like to draw the attention of readers to the timeframe of its cash runway, which lasts until end-September 2024, and to Section 4.2.1 of this report, particularly in relation to the assumptions underlying the going concern basis of accounting adopted by the Board of Directors in the preparation of the Company’s financial statements for the six months ended June 30, 2024.
3 2024 INTERIM FINANCIAL STATEMENTS
Note that the legal provisions applicable to CARMAT, whose shares are traded on Euronext Growth, do not require the issuance of an audit report by the Statutory Auditors on the interim financial statements.
3.1 BALANCE SHEET
Assets (in thousands of euros) |
| June 30, 2024 | Dec. 31, 2023 | |
Gross | Depreciation, amortization and impairment | Net | Net | |
UNCALLED SUBSCRIBED CAPITAL (TOTAL I) |
| |||
Non-current assets | ||||
Intangible assets (notes 4.3.1 and 4.3.2) | ||||
Start-up costs | ||||
Development costs | ||||
Licenses, patents and similar rights | 2,175 | 2,090 | 85 | |
Goodwill(1) | ||||
Intangible assets not yet available for use | 72 | |||
Advances and downpayments | ||||
Property, plant and equipment (notes 4.3.1 and 4.3.2) | ||||
Land | ||||
Buildings | ||||
Technical plant, equipment and tooling | 14,278 | 10,765 | 3,513 | 3,526 |
Other property, plant and equipment | 5,011 | 2,441 | 2,570 | 2,632 |
Property, plant and equipment in progress | 4,030 | 4,030 | 3,794 | |
Advances and downpayments | ||||
Financial assets(2) (notes 4.3.1 and 4.3.2) | ||||
Equity-accounted investments | ||||
Other equity interests | ||||
Other long-term investments | ||||
Loans | ||||
Other financial assets (note 4.3.4) | 543 | 3 | 540 | 613 |
TOTAL II | 26,037 | 15,298 | 10,739 | 10,637 |
Current assets |
| |||
Inventories and work in progress (note 4.3.3) | ||||
Raw materials, supplies | 8,545 | 1,535 | 7,010 | 8,273 |
Work in progress – goods | 2,875 | 1,052 | 1,823 | 1,684 |
Semi-finished and finished goods | 21,911 | 11,548 | 10,363 | 9,220 |
Goods for resale | 6,876 | 3,680 | 3,195 | 4,767 |
Advances and downpayments on orders | 3,618 | 3,618 | 4,071 | |
Receivables(3) | ||||
Trade notes and accounts receivable | 1,830 | 1,830 | 1,348 | |
Other receivables (note 4.3.5) | 2,781 | 144 | 2,637 | 3,797 |
Share capital subscribed, called and unpaid | ||||
Marketable securities | ||||
Cash instruments | ||||
Cash | 11,420 | 11,420 | 8,013 | |
Prepaid expenses(3) (note 4.3.7.4) | 1,517 | 1,517 | 1,222 | |
TOTAL III | 61,373 | 17,959 | 43,413 | 42,394 |
ACCRUAL ACCOUNTS | ||||
Deferred loan issuance costs (IV) | ||||
Bond redemption premiums (V) | ||||
Unrealized foreign exchange losses (VI) | 18 | 18 | 38 | |
Grand total (I+II+III+IV+V+VI) | 87,428 | 33,258 | 54,170 | 53,069 |
(1) Including lease rights. | ||||
(2) Of which are due in less than one year. |
| 72 | 115 | |
(3) Of which are due in more than one year. | 826 |
Equity and liabilities (in thousands of euros) | June 30, 2024 | Dec. 31, 2023 |
EQUITY (note 4.3.6) | ||
Share capital (of which paid-up: €1,405,865.20) | 1,406 | 992 |
Additional paid-in capital | 31,280 | 9,038 |
Revaluation adjustments | 0 | |
Reserves | ||
Legal reserve | 0 | |
Statutory or contractual reserves | 0 | |
Untaxed reserves | 0 | |
Other reserves | 107 | 106 |
Retained earnings/(Losses carried forward) | (47,097) | (1,228) |
Net loss for the period | (26,155) | (53,869) |
Grants | 1,085 | 1,199 |
Tax-driven provisions | 0 | |
TOTAL I | (39,373) | (43,762) |
OTHER EQUITY | ||
Proceeds from issues of equity securities | 0 | |
Conditional advances (note 4.3.7.1) | 16,825 | 16,825 |
TOTAL II | 16,825 | 16,825 |
PROVISIONS | ||
Provisions for contingencies | 678 | 798 |
Provisions for losses (notes 4.3.4 and 4.3.7.6) | 691 | 1,096 |
TOTAL III | 1,369 | 1,894 |
LIABILITIES(1) | ||
Debt | ||
Convertible bonds | 0 | |
Other bonds | 0 | |
Bank loans and borrowings | 33,800 | 47,709 |
Bank overdrafts | 0 | |
Sundry loans and borrowings (note 4.3.5) | 24,700 | 9,940 |
Advances and downpayments received on orders in progress | 0 | |
Accounts payable (note 4.3.5) |
|
|
Trade notes and accounts payable | 5,406 | 9,608 |
Tax and social security payables | 7,063 | 5,928 |
Amounts payable on non-current assets and other | 0 | |
Other payables | 4,370 | 4,908 |
ACCRUAL ACCOUNTS | ||
Prepaid income(1) (note 4.3.7.4) | 0 | |
TOTAL IV | 75,339 | 78,094 |
Unrealized foreign exchange gains | 11 | 18 |
TOTAL V | 11 | 18 |
Grand total (I+II+III+IV+V) | 54,170 | 53,069 |
(1) Liabilities and deferred income due in less than one year. | 12,577 | 37,616 |
3.2 INCOME STATEMENT
Income statement (in thousands of euros) | 6 months 6 months 12 months ended ended ended June 30, 6 months ended June 30, Dec. 31, 2024 June 30, 2024 2023 2023 | ||||
France Export Total Total Total | |||||
OPERATING INCOME |
|
|
| ||
Sale of goods for resale | 65 | ||||
Production sold – goods | 1,725 | 1,495 | 3,220 | 553 | 2,797 |
Production sold – services | |||||
NET REVENUE | 1,725 | 1,495 | 3,285 | 553 | 2,797 |
Inventoried production | 2,831 | 1,905 | 6,001 | ||
Capitalized production | |||||
Operating grants | 363 | 6 | 1,040 | ||
Reversals of impairment, depreciation/amortization and provisions, expense transfers | 8,147 | 7,681 | 8,707 | ||
Other income | 27 | 25 | 51 | ||
TOTAL OPERATING INCOME (I) | 14,653 | 10,169 | 18,596 | ||
OPERATING EXPENSES | |||||
Purchases of goods for resale (including customs duties) | 7 | 901 | 1,202 | ||
Change in inventories (goods for resale) | 306 | (851) | (988) | ||
Purchases of raw materials and other supplies | 3,229 | 4,010 | 8,958 | ||
Change in inventories (raw materials and other supplies) | 546 | (1,211) | (3,171) | ||
Other purchases and external expenses | 12,468 | 12,389 | 27,818 | ||
Taxes, duties and other levies | 142 | 200 | 390 | ||
Wages and salaries | 7,558 | 8,062 | 14,669 | ||
Social security contributions | 3,436 | 3,668 | 6,961 | ||
Depreciation/amortization and impairment | |||||
of non-current assets: depreciation/amortization (note 4.3.2) | 971 | 825 | 1,694 | ||
of non-current assets: impairment | |||||
of current assets: impairment | 10,771 | 7,284 | 11,545 | ||
Additions to provisions for contingencies and losses (note 4.3.4) | 374 | 287 | 1,312 | ||
Other expenses | 255 | 498 | 726 | ||
TOTAL OPERATING EXPENSES (II) | 40,063 | 36,063 | 71,116 | ||
1 – NET OPERATING INCOME (EXPENSE) (I-II) | (25,410) (25,894) | (52,519) | |||
SHARE IN INCOME FROM JOINT VENTURES | |||||
Income allocated or loss transferred (III) | |||||
Loss incurred or income transferred (IV) | |||||
FINANCIAL INCOME | |||||
Investment income | |||||
Income from other marketable securities and non-current asset receivables | |||||
Other interest income |
| 34 | 262 | 373 | |
Reversals of impairment and provisions, expense transfers | 0 | 0 | |||
Foreign exchange gains | 2 | 1 | 3 | ||
Net income on sales of marketable securities | |||||
TOTAL (V) | 35 | 263 | 375 | ||
FINANCIAL EXPENSES | |||||
Depreciation/amortization, impairment and provisions | 3 | 0 | |||
Interest expense | 1,684 | 1,990 | 3,421 | ||
Foreign exchange losses | 13 | 12 | 28 | ||
Net expenses on sales of marketable securities | |||||
TOTAL (VI) | 1,699 | 2,003 | 3,449 | ||
2 – NET FINANCIAL EXPENSE (V-VI) | (1,664) | (1,739) | (3,074) | ||
3 – RECURRING EXPENSE BEFORE TAX (I-II+III-IV+V-VI) | (27 074) | (27 633) | (55 593) | ||
NON-RECURRING INCOME (note 4.4.5) | |||||
Non-recurring income on management transactions | 42 | 42 | 41 | ||
Non-recurring income on corporate actions | 190 | 38 | 210 | ||
Reversals of impairment and provisions, expense transfers | |||||
TOTAL (VII) | 232 | 80 | 251 | ||
NON-RECURRING EXPENSES (NOTE 4.4.5) | |||||
Non-recurring expenses on management transactions | 9 | 36 | 123 | ||
Non-recurring expenses on corporate actions | 86 | 38 | 98 | ||
Depreciation/amortization, impairment and provisions | 3 | ||||
TOTAL (VIII) | 95 | 74 | 225 | ||
4 – NET NON-RECURRING INCOME (VII-VIII) | 137 | 6 | 26 | ||
Employee profit-sharing (IX) | |||||
Income tax (X) (note 4.4.4) | (782) | (954) | (1,698) | ||
TOTAL INCOME (I+III+V+VII) | 14,919 | 10,512 | 19,223 | ||
TOTAL EXPENSES (II+IV+VI+VIII+IX+X) | 41,074 | 37,185 | 73,092 | ||
5 – NET PROFIT (LOSS) (TOTAL INCOME – TOTAL EXPENSES) | (26,155) | (26,673) | (53,869) | ||
4 NOTES TO THE 2024 INTERIM FINANCIAL STATEMENTS
The following sections contain notes to the balance sheet at June 30, 2024, which shows total assets of €54.170 million, and to the income statement for the six months then ended, presented in list form and showing €3.3 million in revenue and a net loss of €26.155 million.
The reporting period covers the six months from January 1, 2024 to June 30, 2024.
The notes and tables presented below are an integral part of the financial statements for the six months ended June 30, 2024, as approved by the Board of Directors on September 5, 2024. They are presented in thousands of euros unless otherwise stated.
4.1 SIGNIFICANT EVENTS DURING THE PERIOD
Activity
In the first six months of 2024, CARMAT generated €3.3 million in revenue, which means that it has already exceeded its full-year revenue for 2023 (€2.8 million). The first-half 2024 revenue figure corresponds to the sale of 20 artificial hearts (compared with three in the first half of 2023), seven of which were commercial implants (in Germany, Italy and Poland) and 13 were part of the EFICAS clinical study in France.
The rate of Aeson® implants reached four per month in the second quarter, doubling from two hearts per month in the first quarter.
Sales were generated for the first time in Poland, bringing the number of countries in which CARMAT has a commercial activity to three (Germany, Italy and Poland). A total of nine hospitals carried out their first Aeson® implants in the first half of 2024 – four in Germany, three in France and two in Poland – and at June 30, 2024, 42 hospitals (in 14 different countries) had been trained to perform commercial implants of Aeson® hearts, i.e., nine more than at end-2023.
This very positive trend reflects the encouraging take-up of CARMAT’s artificial heart therapy in Europe.
Financing
Debt restructuring:
In March 2024, CARMAT reached an agreement with all of its lenders (the EIB, BNPP and BPI) on new repayment terms for its bank loans. In particular, the agreement provides for the final maturity of each of the loans to be extended by between 24 and 30 months, and for the equitization of the EIB loan[14].
This debt restructuring provides the Company with the certitude of reducing its loan repayments by more than €30 million between 2024 and 2025[15] and it also means that CARMAT can expect to see a significant reduction in its cash repayments between 2026 and 2028 as a result of the equitization process (which began on June 13, 2024 for the first tranche of the loan).
Capital increases:
The Company also carried out two capital increases in the first half of 2024 – one in January and the other in May – which generated gross proceeds of €16.5 million and €16.0 million respectively. CARMAT 's major shareholders, Sante Holdings, and Lohas/Les Bastidons (Pierre Bastid), took up a significant number of the shares issued, demonstrating their strong support of the Company.
Cash runway:
Based on its current business plan, CARMAT’s[16] confirmed financial resources should enable it to fund its operations until September 30, 2024[17]. The Company is actively working on various financing options to secure the financial resources it requires to continue as a going concern beyond that date.
Net loss
The Company reported a €26.2 million net loss for the first half of 2024, representing an improvement of more than €2 million compared with the €26.7 million net loss figure for first-half 2023.
SIGNIFICANT EVENTS AFTER THE REPORTING DATE
No events occurred after the reporting date that are liable to alter the presentation or valuation of the interim financial statements as authorized for issue by the Board of Directors on September 5, 2024.
4.2 SIGNIFICANT ACCOUNTING POLICIES
The methods used for measuring accounting items for the period remain unchanged from the previous period.
4.2.1 GENERAL PRINCIPLES AND CONVENTIONS
The Company’s financial statements have been prepared in accordance with French generally accepted accounting rules and principles as set out in the French General Chart of Accounts (ANC Standard 2014-03 on the Chart of Accounts issued by the French accounting standards-setter – Autorité des Normes Comptable [ANC]). The historical cost method is used as the basis for measuring accounting items.
The accounting conventions have been applied in accordance with the provisions of the French Commercial Code (Code de commerce), the Accounting Decree of November 29, 1983 and the CRC regulations concerning the new French General Chart of Accounts applicable at the end of the reporting period.
The financial statements for the six months ended June 30, 2024 have been prepared in accordance with French generally accepted accounting principles, including the principles of prudence and accrual-based accounting. They are presented on a going concern basis and accounting methods have been applied consistently from one period to the next.
Going concern basis
Given its stage of development, CARMAT is not yet cash flow-positive, and based on its current business plan, does not expect to be self-financing for several years yet. At this stage, it is therefore dependent on external financing (capital increases, borrowings, subsidies and other types of financing).
Based purely on its current confirmed financial resources, CARMAT can fund its operations (on the basis of its updated business plan) until the end of September 2024 without the need for any further financing. The Company estimates its financing requirements over the next 12 months to be c. €45 million (of which €12 million to €15 million by December 31, 2024).
Based on the progress of its project, the results of its clinical trials, the volumes of Aeson® sales already achieved, the positive feedback it has received and the interest shown by the medical community for its device, as well as its output potential, its previous financing and all other information in its possession, the Company considers the probability that it will be unable to source the funds it needs to continue operating to be moderate, although it cannot be completely ruled out. Indeed, the current geopolitical, political, economic and financial context could in the short term make it more difficult for CARMAT to secure the financing it requires. In addition, securing such financing is partly contingent on the Company successfully rolling out its business plan, especially in terms of sales growth.
Accordingly, the Company intends to gradually extend its cash runway to 12 months. This will take place over several stages: first, by carrying out a capital increase in the very near-term, which should enable it to strengthen its cash position and therefore continue as a going concern beyond September 2024, and subsequently by launching additional initiatives (including further capital increases) enabling it to further extend its cash runway. Moreover, the Company’s forecast sales growth should enhance CARMAT’s attractiveness to investors, and this, combined with strict financial discipline, should allow it to gradually reduce the amount of cash used in its operating and investing activities.
In this regard, the Company has an ongoing active investor relations policy targeting both French and international investors, and is constantly on the lookout for new financing opportunities (equity, government support and other types of financing). It believes that it can also count, to some extent, on the support of some of its main existing shareholders.
Based on these factors, the Board of Directors believes that the going concern basis is appropriate. However, there is no guarantee that the anticipated financing will be secured. This gives rise to significant uncertainty, which could jeopardize the Company's ability to continue as a going concern. For example, if it is unable to secure the financing it needs, application of French accounting principles could prove inappropriate in the normal course of business, in particular with regard to the measurement of assets and liabilities, and the Company could be placed in receivership in the short or medium term.
4.2.2 ADDITIONAL INFORMATION
4.2.2.1 Applied research and development costs
Research and development costs are recognized as expenses in the year in which they are incurred.
4.2.2.2 Intangible assets
Patents, licenses and other intangible assets have been measured at their acquisition cost, excluding the expenses incurred in acquiring them.
The methods and periods of amortization used are as follows:
4.2.2.3 Property, plant and equipment
The gross value of property, plant and equipment corresponds to their initial book value, inclusive of any expenditure required to render the items usable, excluding costs incurred in their acquisition.
The methods and periods of depreciation used are as follows:
Category | Method | Useful life |
Fixtures and fittings | Straight line | 9 to 10 years |
Technical plant | Straight line | 3 to 10 years |
Equipment and tooling | Straight line | 2 to 6 years |
Furniture | Straight line | 8 years |
IT equipment | Straight line | 3 years |
4.2.2.4 Financial assets
- Other financial assets
In 2010, the Company entered into a liquidity agreement, the purpose of which was to improve the liquidity of transactions and regularize the CARMAT share price, without impeding the normal operation of the market and without misleading third parties. As part of the 2010 agreement, the Company made €300,000 available.
Treasury shares acquired through the implementation of this liquidity agreement are recorded under financial assets. If necessary, an impairment loss is recognized based on CARMAT’s share price at the end of the reporting period.
Other financial assets are composed of the following:
- guarantee deposits paid, which are shown at face value;
- the unused balance of sums made available under the liquidity agreement for the acquisition of treasury shares.
4.2.2.5 Receivables and payables
Receivables and payables are measured at face value. Where applicable, receivables are impaired via provisions to take into account any collection difficulties they may potentially face. Any provisions for impairment are determined by comparison between the acquisition value and the probable realizable value.
4.2.2.6 Revenue
Sales are recognized when ownership is transferred to the customer.
4.2.2.7 Translation differences and foreign exchange gains and losses
Payables and receivables in foreign currencies are measured at the reporting date exchange rate. Any resulting translation differences are recorded in the balance sheet under “Unrealized foreign exchange gains” or “Unrealized foreign exchange losses”, as appropriate.
A provision is booked for the full amount of any unrealized foreign exchange losses.
Unrealized gains are not recorded in the income statement.
Foreign exchange gains and losses on trade receivables and payables are recognized as operating income or expenses.
4.2.2.8 Inventories
According to the French Commercial Code and Chart of Accounts (Article 211-7), inventories are assets that meet the following criteria:
- they are identifiable items that will generate future economic benefits, are controlled by the company, and their cost can be measured reliably;
- they are held for sale in the ordinary course of business or in the form of materials or supplies to be consumed in the production process or in the rendering of services.
The Company’s inventories and work in progress comprise goods, raw materials and other supplies, semi-finished and finished goods, and work in progress in the production process.
Inventories and work in progress are measured at the reporting date using the methods set out in the French Chart of Accounts. Items are monitored individually and are clearly identifiable. An impairment provision is taken if their realizable value falls below their carrying amount.
Impairment is calculated taking the following factors into account:
- the life cycle of items of inventory and work in progress (obsolete or short shelf-life items, damaged items or items that do not meet the requisite quality standards, etc.);
- the different outlook for inventory items, distinguishing between items intended for sale and items intended for other, non-revenue-generating activities (e.g., clinical trials, training, tests, etc.). Inventories intended for other activities are fully impaired.
When the recoverable amount at year-end (market value for finished goods and goods for resale and value in use for work in progress and raw materials) is less than the carrying amount, a provision for impairment is recognized for the difference.
Impairment provisions are recognized by inventory category.
4.2.2.9 Cash in euros
Cash on hand or at bank is recorded at face value.
4.2.2.10 Cash in foreign currencies
Cash in foreign currencies is converted into euros at the exchange rate prevailing at the reporting date. Translation differences are recognized directly in profit or loss for the period as foreign exchange gains and losses.
4.2.2.11 Cash and cash equivalents
For the purposes of the cash flow statement, cash and cash equivalents are defined as being:
- the sum of the “Cash instruments” and “Cash” items on the assets side of the balance sheet, to the extent that cash instruments are available in the very short term and do not present a risk of a loss in value in the event of a change in interest rates;
- less the “Bank overdrafts” item on the liabilities side of the balance sheet.
4.2.2.12 Repayable advances made by public bodies
Advances received from public bodies to finance the Company’s operations and repayable subject to conditions are shown in liabilities under “Other equity – Conditional advances”. The corresponding interest is shown in balance sheet liabilities under “Sundry loans and borrowings”.
4.2.2.13 Equitized borrowings
Amounts due in relation to financial liabilities that are “equitized" via a trust[18] are shown (principal and accrued interest) in balance sheet liabilities under "Sundry loans and borrowings".
4.2.2.14 Grants
If subsidies are tied to the achievement of specific milestones or programs, they are included in “Other payables” in the balance sheet when they are received.
1. If subsidies are contractually likely to have to be repaid in full if the subsidized program is not completed, they continue to be recorded under "Other payables" until the final milestone has been achieved, after which they are recorded: o either in income for the period as an operating subsidy if they relate to operating activities; o or on the liabilities side of the balance sheet as an investment subsidy if they relate to investments; portions of the subsidy will then be recorded as non-recurring income as and when the assets concerned by the subsidy are amortized.
2. Otherwise, when the milestones defined in the relevant contracts are achieved, they are recorded:
o either in income for the period as an operating subsidy if they relate to operating activities; o or on the liabilities side of the balance sheet as an investment subsidy if they relate to investments; portions of the subsidy will then be recorded as non-recurring income as and when the assets concerned by the subsidy are amortized.
4.2.2.15 Retirement benefits
Future payments in respect of benefits granted to employees are measured according to an actuarial method (method 2 based on IAS 19 as amended published in June 2011, in compliance with ANC recommendation no. 2013-02 dated November 7, 2013), taking account of assumptions concerning changes in salaries, retirement age and mortality. The resulting amounts are then discounted to present value and entitlement capped according to the collective bargaining agreement for the metallurgy industry. These obligations are covered by provisions recorded as liabilities in the balance sheet.
4.2.2.16 Provisions for losses
Warranty provision
In addition to the legal guarantee of conformity provided for in Article 1604 of the French Civil Code and the warranty against hidden defects provided for in Article 1641 of said Code, the Company may grant customers, within the framework of its commercial offer, a commercial warranty which consists of the free supply of a certain number of replacement components, under certain limited contractually defined terms and for a contractually defined limited period of time. The Company therefore records a provision for losses at the time the product is sold, in accordance with the matching principle for income and expenses set out in the French Chart of Accounts. The amount of the provision is based on the contractually defined terms of the guarantee and statistical considerations. The provision is subsequently written back as necessary, to the extent of the expenses actually incurred in connection with the implementation of the guarantee and/or when the guarantee is extinguished.
Provision for social security levies on free shares
The Company periodically grants free shares to certain employees. A 20% social security levy on the value of the free shares is payable by the Company when the shares are fully vested by their beneficiaries. The Company therefore records a provision for expenses prorated over the vesting period (i.e., the period between the provisional grant date and the final vesting date of the shares). The provision is reversed when the social security levy is paid.
4.2.2.17 Sub-contracting expenses
The progress of third-party sub-contracting agreements for certain services is assessed at the end of each reporting period in order to allow the cost of services already rendered to be recorded under accrued expenses.
4.2.2.18 Share issue costs
In application of the reference method (ANC 2018-01), share issue costs are recorded in the balance sheet as deductions from the share premium.
4.2.2.19 Borrowing costs
Borrowing costs are expensed as incurred.
4.3 ADDITIONAL INFORMATION ON THE BALANCE SHEET
4.3.1 MOVEMENTS IN NON-CURRENT ASSETS
Non-current assets – gross value (in thousands of euros) | Gross value at start of period | Increases | |||
Line to line Acquisitions transfers | |||||
Licenses, patents and similar rights(1) | 2,073 | 102 | |||
Intangible assets not yet available for use | 72 | ||||
TOTAL | 2,145 | 102 | |||
Technical plant, equipment and industrial tooling(2) | 13,801 | 680 | 26 | ||
General plant, sundry fixtures and fittings | 4,050 | 59 | 90 | ||
Office and IT equipment, furniture | 785 | 27 | |||
Property, plant and equipment in progress | 3,794 | 1,125 | |||
TOTAL | 22,429 | 739 | 1,268 | ||
Other financial assets(3) | 613 | 1,781 | |||
TOTAL | 613 | 0 | 1,781 | ||
GRAND TOTAL | 25,187 | 841 | 3,049 | ||
Non-current assets – gross value (in thousands of euros) | Decreases | Gross value at end of period | Revaluation of original value at end of period |
Disposals – Line to line Retirement transfers s |
Licenses, patents and similar rights(1) 2,175
Intangible assets not yet available for use | 72 | |||
TOTAL | 0 | 72 | 2,175 |
|
Technical plant, equipment and industrial tooling(2) | 229 | 14,278 | ||
General plant, sundry fixtures and fittings | 4,199 | |||
Office and IT equipment, furniture | 813 | |||
Property, plant and equipment in progress | 841 | 47 | 4,030 | |
TOTAL | 841 | 276 | 23,319 |
|
Other financial assets(3) | 1,851 | 543 | ||
TOTAL | 1,851 | 543 | ||
GRAND TOTAL | 841 | 2,199 | 26,037 |
|
(1) This item includes a sum of €411,284, recognized in respect of the share of the contribution in kind of €960,000 made on September 30, 2008, corresponding to the contribution of patents.
(2) The item also includes a sum of €548,716 recognized in respect of the share of the contribution in kind of €960,000 made on September 30, 2008, corresponding to the contribution of equipment and tooling.
(3) This item includes the 17,070 treasury shares held in connection with the liquidity agreement, valued at €0.029million, the liquidities not invested in treasury shares at the end of the period under the liquidity agreement for €0.042 million, and guarantee deposits of €0.471 million, comprising deposits under premises lease contracts.
4.3.2 MOVEMENTS IN DEPRECIATION AND AMORTIZATION
Positions and movements for the period (in thousands of euros) | Value at start of period | Additions for the period | Decreases Reversals | Value at end of period | |
Licenses, patents and similar rights | 2,073 | 17 | 2,090 | ||
TOTAL | 2,073 | 17 | 0 | 2,090 | |
Technical plant, equipment and industrial tooling | 10,275 | 715 | 10,990 | ||
General plant, sundry fixtures and fittings | 1,751 | 184 | 225 | 1,710 | |
Office and IT equipment, furniture | 452 | 54 | 506 | ||
TOTAL | 12,477 | 954 | 225 | 13,206 | |
GRAND TOTAL | 14,550 | 971 | 225 | 15,295 |
4.3.3 MOVEMENTS IN INVENTORIES
Inventories – gross value (in thousands of euros) | Value at start Value at end Increases Decreases of period of period | |||
Raw materials, supplies | 9,091 | 2,936 | 3,481 | 8,545 |
Work in progress – goods | 2,562 | 2,812 | 2,499 | 2,875 |
Semi-finished and finished goods | 19,394 | 14,360 | 11,843 | 21,911 |
Goods for resale | 7,182 | 410 | 717 | 6,876 |
TOTAL | 38,229 20,518 18,540 40,207 | |||
Inventories – impairment(1) (in thousands of euros) | Value at start Additions for of period the period | Decreases Reversals | Value at end of period | |
Raw materials, supplies | 818 | 927 | 210 | 1,535 |
Work in progress – goods | 878 | 1,034 | 860 | 1,052 |
Semi-finished and finished goods | 10,174 | 7,533 | 6,159 | 11,548 |
Goods for resale | 2,415 | 1,276 | 11 | 3,680 |
TOTAL | 14,285 10,770 | 7,241 | 17,815 | |
(1) Impairment for the period breaks down as follows by type:
- impairment related to the life cycle of items of inventory (€15.0 million);
- impairment of inventories intended for non-revenue-generating activities (€2.8 million).
A 10-point change in the portion of inventories intended for non-revenue-generating activities (clinical trials, training, R&D tests) would have a €1.4 million impact on the amount of impairment related to estimated intended use.
4.3.4 MOVEMENTS IN PROVISIONS
Provisions (in thousands of euros) | Value at Increases start of Additions period | Decreases Utilized amounts | Decreases Surplus amounts | Value at end of period | |
Sundry risks(1) | 759 | 279 | 230 | 149 | 659 |
Foreign exchange losses | 38 | 18 | 38 | 18 | |
Pension and similar obligations(2) | 473 | 69 | 542 | ||
Social security levies on free shares(3) | 623 | 7 | 482 | 149 | |
TOTAL | 1,894 | 374 | 230 | 669 | 1,369 |
Impairment of inventories and work in progress | 14,285 | 10,770 | 986 | 6,255 | 17,815 |
Impairment of other receivables | 144 | 144 | |||
Impairment of financial assets | 3 | 3 | |||
TOTAL | 14,429 | 10,773 | 986 | 6,255 | 17,962 |
GRAND TOTAL | 16,323 11,147 | 1,215 | 6 924 | 19,330 | |
Of which operational additions and
16,323 11,144 1,215 6,924 19,327 reversals:
Of which financial additions and reversals: 3 3
(1) At June 30, 2024, this amount mainly comprised: - employee-related provisions;
- the provision for commercial guarantees (see note 4.3.7.6).
(2) See note 4.6.3.1.
(3) See note 4.3.7.6.
4.3.5 RECEIVABLES AND PAYABLES BY MATURITY
Receivables by maturity (in thousands of euros) | Gross amount | Due within 1 year | Due beyond 1 year | |
Trade receivables | 1,830 | 1,830 | ||
Total trade receivables | 1,830 | 1,830 |
| |
| ||||
Other receivables (in thousands of euros) | Gross amount | Due within 1 year |
| Due beyond 1 year |
Social security receivables | 94 | 94 | ||
Income tax(1) | 1,416 | 590 | 826 | |
Value-added tax | 1,073 | 1,073 | ||
Sundry receivables | 198 | 198 | ||
Total other receivables | 2,781 | 1,955 | 826 | |
(1) Income tax receivable corresponds to the research tax credit for the first half of 2024, plus the balance of the 2023 research tax credit that remains due.
Payables by maturity (in thousands of euros) | Gross amount | Due within 1 year | Due in 1 to 5 years | Due beyond 5 years |
Bank loans and borrowings(1) | 33,796 | 1,158 | 32,639 | |
Sundry loans and borrowings(2) | 24,700 | 17,178 | 7,522 | |
Interest due on current account | 4 | 4 | ||
Trade notes and accounts payable | 5,406 | 5,406 | ||
Staff and related payables | 2,984 | 2,984 | ||
Social security payables | 3,927 | 2,873 | 1,053 | |
Value-added tax | ||||
Other taxes, duties and levies | 153 | 153 | ||
Total payables | 70,969 | 12,577 | 50,870 | 7,522 |
(1) This amount corresponds to bank loans (see details below) including related accrued interest payable.
(2) Including loans equitized (interest and principal) via a trust. See the breakdown in the table below.
Breakdown of bank loans (in thousands of euros) | Gross amount | Due within 1 year | Due in 1 to 5 years(2) | Due beyond 5 years | |||
EIB loan – principal(1) | 20,000 | 20,000 | |||||
EIB loan – accrued interest | 4,245 | 163 | 4,082 | ||||
BPI government-guaranteed loan – principal | 5,000 | 729 | 4,271 | ||||
BPI government-guaranteed loan – accrued interest | 66 | 66 |
| ||||
BNP Paribas government-guaranteed loan – principal | 4,484 | 198 | 4,286 | ||||
BNP Paribas government-guaranteed loan – accrued interest | 2 | 2 |
| ||||
Total | 33,796 | 1,158 | 32,639 | ||||
(1) Loan from the European Investment Bank (EIB): the EIB loan contract provides for certain information and operational commitments (such as limitations on authorized debt, authorized external growth operations, transfers of assets, etc.), the non-compliance of which would allow the EIB, if it deemed it necessary, to demand an early repayment of the loan. The occurrence of certain changes in the shareholding structure or a change in management not approved beforehand by the EIB would also allow the latter, if deemed necessary following discussions with the Company, to demand an early repayment of the loan. To date, CARMAT complies with all of the commitments required by the EIB.
(2) Including €2.5 million payable withing 2 years, €2.5 million payable withing 3 years and the remaining amount (i.e. €27.6 million) payable
within 4 to 5 years.
Breakdown of Sundry loans and borrowings (in thousands of euros) | Gross amount | Due within 1 year | Due in 1 to 5 years (2) | Due beyond 5 years |
Equitized EIB loan (tranche 1) – Principal and accrued interest(1) | 14,719 | 14,719 | ||
BPI conditional advances – Accrued interest | 9,981 | 2,459 | 7,522 | |
Total | 24,700 |
| 17,178 | 7,522 |
(1) See Section 4.6.2.
(2) Including €0.2 million payable withing 2 years, €14.9 million payable withing 3 years and the remaining amount (i.e €2.1 million) payable
within 4 to 5 years.
4.3.6 SHARE CAPITAL
Class of shares | Par value in euros | Number of shares | |||
Opening | Created Canceled Redeemed | Closing | |||
Ordinary shares | 0.04 | 24,749,788 | 10,365,421 | 35,115,209 | |
Preference shares | 0.04 | 38,248 | 2,363 9,190 | 31,421 | |
TOTAL |
|
| 24,788,036 | 10,367,784 9,190 | 35,146,630 |
Changes in the Company’s share capital in the first half of 2024 are detailed in note 4.3.6.1 below.
4.3.6.1 Changes in equity
(in thousands of euros) | Number of shares | Capital | Additional paid-in capital | Additional paidin capital Reserves expenses | Retained earnings/ (Losses carried forward) | Investment Net loss subsidies | Equity | |||||||||
At December 31, 2023 | 24 788 036 | 991,52 | 15 991 | (6,953) 106 | (1,228) | (53,869) 1 199 | (43,762) | |||||||||
Appropriation of net loss(1) | (8,000) | (45,869) | 53,869 | |||||||||||||
Net loss for the period | (26,155) | (26,155) | ||||||||||||||
Capital increase (January fundraising) | 4 141 470 | 165,66 | 16 359 | 16 524 | ||||||||||||
Conversion of AGAP 2017-03 preference shares into ordinary shares | 55 080 | 2,20 | (2) | |||||||||||||
Conversion of AGAP 2018-01 preference shares into ordinary shares | 29 700 | 1,19 | (1) | |||||||||||||
Conversion of AGAP 2018-02 preference shares into ordinary shares | 105 000 | 4,20 | (4) | |||||||||||||
Conversion of AGAP 2018-03 preference shares into ordinary shares | 27 380 | 1,10 | (1) | |||||||||||||
Vesting of AGA 2022-02 free shares | 8 160 | 0,33 | 0 | |||||||||||||
Vesting of AGAP 2019-01 free preference shares | 400 | 0,02 | 0 | |||||||||||||
Cancellation of Portzamparc invoice for 2017 fundraising | 132 | 132 | ||||||||||||||
Capital increase (May fundraising) | 5 333 422 | 213,34 | 15 787 | 16 000 | ||||||||||||
Equitization of EIB loan(2) | 193 143 | 7,73 | 425 | 433 | ||||||||||||
Vesting of AGA June 2023-01 free shares | 247 789 | 9,91 | (10) | |||||||||||||
Vesting of AGA June 2022-02 free shares | 97 587 | 3,90 | (4) | |||||||||||||
Vesting of AGA June 2021-03 free shares | 117 500 | 4,70 | (5) | |||||||||||||
Vesting of AGAP 2023 free preference shares | 1 963 | 0,08 | 0 | |||||||||||||
Allocation of AGA June 2024 free shares | (28) | 28 | ||||||||||||||
Allocation of AGAP June 2024 free preference shares | (1) | 1 | ||||||||||||||
Portion of CAP23 investment subsidy recognized in income | (97) | (97) | ||||||||||||||
Portion of “Plan 2030” investment subsidy recognized in income | (17) | (17) | ||||||||||||||
Costs related to capital increases | (2,433) | (2,433) | ||||||||||||||
At June 30, 2024 | 35 146 630 | 1 405,87 | 40,666 | (9,386) | 107 | (47,097) | (26,155) | 1,085 | (39,373) | |||||||
(1) As decided by the Combined Shareholders’ Meeting of May 30, 2024.
(2) Capital increases carried out through the issuance of shares on exercise of warrants by the Trust.
4.3.6.2 Other securities giving access to the share capital – Stock options
There were no longer any outstanding stock options at June 30, 2024.
4.3.6.3 Other securities giving access to the share capital – Free shares
Free shares awarded during the period
The free share plans (AGA June 2024-01, AGA June 2024-02 and AGA June 2024-03) of June 24, 2024 led to the award of 705,957 ordinary shares (including 225,515 under the AGA June 2024-01, 225,515 under the AGA June 2024-02 and 254,927 under the AGA June 2024-03). These shares vest on the following dates: June 24, 2025 for the AGA June 2024-01 shares, which are subject to a two-year lock-up period; June 24, 2026 for the AGA June 2024-02 shares, which are subject to a one-year lock-up period; and June 24, 2027 for the AGA June 2024-03 shares, which are not subject to a lock-up period.
The preference share plan (AGAP 2024) of June 24, 2024 led to the award of 12,818 AGAP 2024 preference shares. Of these shares, 12,200 vest on June 24, 2025 and the remaining 618 vest on June 24, 2027. All of the shares can be converted into a maximum of 100 ordinary shares each as from June 24, 2027, based on the achievement of performance conditions.
Summary table of free shares
AGAP/AGA shares awarded | AGAP/AGA shares expired | AGAP/AGA shares vested | AGAP vested and already converted into ordinary shares | AGAP to be converted into ordinary shares and nonconvertible AGAP | Number of ordinary shares issued | Maximum number of ordinary shares yet to be issued (a) | Net number of new shares that may be created (b) | ||
AGAP 2017-03 (SM of April 27, 2017) | 3 490 | 3 490 | 3 250 | 240 | 173 050 | 3 300 | 3 240 | ||
AGAP 2018-01 (SM of April 2018) | 5, | 580 | 580 | 500 | 80 | 50 000 | 8 000 | 7 920 | |
AGAP 2018-02 (SM of April 2018) | 5, | 11 500 | 200 | 11 300 | 8 650 | 2 650 | 127 000 | 39 250 | 36 600 |
AGAP 2018-03 (SM of April 2018) | 5, | 740 | 740 | 370 | 370 | 27 750 | 27 750 | 27 380 | |
AGAP 2019-01 (SM of March 2019) | 28, | 8 000 | 120 | 7 660 | 7 880 | 0 | 32 400 | 24 740 | |
AGAP 2019-02 (SM of March 2019) | 28, | 8 000 | 120 | 7 880 | 200 | 7 680 | 2 000 | 76 800 | 69 120 |
AGAP 2019-03 (SM of March 2019) | 28, | 3 600 | 60 | 3 540 | 3 540 | 0 | 0 | ||
AGAP 2020-01 (SM of March 2020) | 30, | 2 360 | 2 160 | 2 360 | 236 000 | 233 840 | |||
AGAP 2020-02 (SM of March 2020) | 30, | 900 | 820 | 900 | 90 000 | 89 180 | |||
AGA 2021-03 (SM of May 2021) | 12, | 117 500 | 117 500 | N/A | N/A | 117 500 | 0 | ||
AGA 2022-02 (SM of May 2021) | 12, | 8 970 | 810 | 8 160 | N/A | N/A | 8 160 | 0 | |
AGA 2022-03 (SM of May 2021) | 12, | 19 850 | 0 | N/A | N/A | 19 850 | 19 850 | ||
AGAP 2022 (SM of May 2022) | 11, | 4 654 | 4 258 | 4 654 | 465 400 | 461 142 | |||
AGA June 22-02 (SM of May 11, 2022) | 97 587 | 97 587 | N/A | N/A | 97 587 | 0 | |||
AGA June 22-03 (SM of May 11, 2022) | 124 816 | N/A | N/A | 124 816 | 124 816 | ||||
AGA June 23-01 (SM of May 11, 2023) | 250 989 | 3 200 | 247 789 | N/A | N/A | 247 789 | 0 | ||
AGA June 23-02 (SM of May 11, 2023) | 194 643 | N/A | N/A | 194 643 | 194 643 | ||||
AGA June 23-03 (SM of May 11, 2023) | 191 330 | N/A | N/A | 191 330 | 191 330 | ||||
AGAP 2023 (SM of May 11, 2023) | 2 171 | 32 | 1 963 | 2 139 | 213 900 | 211 937 | |||
AGA June 24-01 (SM of May 30, 2024) | 225 515 | N/A | N/A | 225 515 | 225 515 | ||||
AGA June 24-02 (SM of May 30, 2024) | 225 515 | N/A | N/A | 225 515 | 225 515 | ||||
AGA June 24-03 (SM of May 30, 2024) | 254 927 | N/A | N/A | 254 927 | 254 927 | ||||
AGAP 2024 (SM of May 30, 2024) | 12 818 | 1 281 800 | 1 281 800 | ||||||
Total | 1 874 022 | 954 403 | 3 711 196 | 3 683 495 | |||||
(a) Assuming that (i) all AGAP shares awarded and not forfeited are converted into ordinary shares, less any ordinary shares already issued, and (ii) all AGA shares awarded vest for their beneficiaries, less those already vested.
(b) Representing a maximum dilution of 10.5% compared to the existing capital.
4.3.6.4 Other securities giving access to the share capital – Share warrants (BSA)
Share warrants awarded during the period
6,000,000 share warrants were issued free of consideration to IQEQ on June 13, 2024 as part of the equitization of the loan taken out with the European Investment Bank (EIB) (see Section 4.6.2).
Summary table of BSA share warrants
| Issued | Subscribed | Expired | Reserve | Exercised | Balance | % of existing share capital | Expiry date |
BSA 2017 (SM of April 27, 2017) | 12,000 | 12,000 | 12,000 | 0.03% | May 15, 2027 | |||
BSA 2018 (SM of April 5, 2018) | 10,000 | 10,000 | 10,000 | 0.03% | June 11, 2028 | |||
BSA 2019 (SM of March 28, 2019) | 6,000 | 6,000 | 6,000 | 0.02% | June 24, 2029 | |||
BSA 2021 (SM of May 12, 2021) | 12,000 | 12,000 | 12,000 | 0.03% | June 14, 2031 | |||
BSA 2023 (SM of May 11, 2021) | 20,000 | 20,000 | 20,000 | 0.06% | Feb. 21, 2033 | |||
BSA 2023 (SM of May 11, 2023) | 6,000 | 6,000 | 6,000 | 0.02% | May 11, 2033 | |||
BSA 2024 – Equitization (SM of May 30, 2024) | 6,000,000 | 6,000,000 | 193,143 | 5,806,857 | 16.52% | June 13, 2028 |
4.3.7 OTHER BALANCE SHEET DETAILS
4.3.7.1 Conditional advances
The “Conditional advances” line item comprises (i) repayable advances received from Bpifrance, which totaled €14,507,309 at June 30, 2024, and (ii) the “Plan Santé 2030” repayable advance amounting to €2,318,047, granted to CARMAT in April 2023.
The advances from Bpifrance bear interest at the contracted rate of 5.59%, while the Plan Santé 2030 advance bears interest at 3.56%. The interest accrued, calculated using the capitalization method, stood at €9.981 million at the period-end and is recorded in liabilities under “Sundry loans and borrowings”.
4.3.7.2 Accrued income
Amount of accrued income included in the following balance sheet items (in thousands of euros) | Value |
Trade receivables | |
Other receivables | 870 |
Subsidies receivable | 20 |
Total accrued income | 890 |
4.3.7.3 Accrued expenses
Amount of accrued expenses included in the following balance sheet items (in thousands of euros) | Value | |
Royalties | 48 | |
Bank loans and borrowings | 1,158 | |
Sundry loans and borrowings | 10,471 | |
Trade notes and accounts payable | 2,705 | |
Tax and social security payables | 4,389 | |
Other payables | 173 | |
Total accrued expenses | 18,944 |
4.3.7.4 Prepaid expenses and deferred income
Prepaid expenses (in thousands of euros) | Value | |
Operating expenses | 1,517 | |
Total prepaid expenses | 1,517 |
Prepaid expenses include the portion of rent, software license fees, insurance premiums and other fees already paid but relating to the period after June 30, 2024.
Prepaid income (in thousands of euros) | Value |
Operating income | None |
Total prepaid income | None |
4.3.7.5 Information on related companies
The following balance sheet items include sums in connection with related companies:
Trade notes and accounts payable (in thousands of euros) |
| None |
4.3.7.6 Provisions for losses
Free shares
At June 30, 2024, a provision for losses of €0.149 million had been recorded for the 20% social security levy due on free shares awarded but not yet vested. This levy is payable when the shares vest.
The calculation assumptions used to determine the amount of the provision are as follows:
- estimated percentage of achievement for each performance criterion, where applicable;
- value of an ordinary share: €2.345 (closing price on June 30, 2024);
- employer contribution rate (social security levy): 20%.
Commercial warranty
As part of its commercial offer, the Company may grant customers a “commercial warranty” (free replacement of a certain number of replacement components for a given period, under certain limited contractually defined conditions).
The corresponding provision amounted to €0.257 million at June 30, 2024.
4.4 ADDITIONAL INFORMATION ON THE INCOME STATEMENT
4.4.1 SALES
The Company recorded revenue of €3.28 million for first-half 2024, corresponding to the sale of 20 Aeson® artificial hearts – seven for commercial implants (in Germany, Italy and Poland) and 13 as part of the EFICAS clinical study in France.
4.4.2 GRANTS
Operating grants
In the first half of 2024, the Company recognized a total of €0.363 million in operating subsidies in its income statement, corresponding to:
- €0.014 million in subsidies received in respect of employer apprenticeship programs;
- €0.349 million for the last payment of the €1.4 million “CAP 23” subsidy awarded to CARMAT in its capacity as a winner of the “Industrial Recovery Plan – Strategic Sectors” call for projects.
Investment subsidy
In the first half of 2024, the Company recognized a portion of an investment subsidy for €0.114 million under non-recurring income, breaking down as:
- €0.097 million of the CAP 23 subsidy mentioned above;
- €0.017 million of the €13.2 million blended financing package awarded to CARMAT in April 2023 under the “France 2030 (Health)” plan.
4.4.3 APPLIED RESEARCH AND DEVELOPMENT COSTS
Research and development expenditure represented €6.320 million in first-half 2024.
4.4.4 RESEARCH TAX CREDIT
The income statement for the first half of 2024 includes a research tax credit for an estimated €0.782 million, calculated using the same methods as in prior years.
4.4.5 NON-RECURRING INCOME AND EXPENSES
Non-recurring income and expenses (in thousands of euros) | 6 months ended June 30, 2024 | 12 months ended Dec. 31, 2023 | 6 months ended June 30, 2023 |
Non-recurring income
• Various adjustments | 42 | 41 | 42 |
• Portion of investment grants transferred to income | 114 | 126 | 21 |
• Disposal of treasury shares | 76 | 84 | 17 |
Total | 232 | 251 | 80 |
Non-recurring expenses
• Various adjustments | 9 | 123 | 36 |
• Disposal of treasury shares | 86 | 98 | 38 |
• Non-recurring depreciation/amortization | 0 | 3 | |
Total | 95 | 225 | 74 |
4.4.6 INFORMATION ON RELATED COMPANIES
The following income statement items include sums in connection with related companies:
Other purchases and external charges (in thousands of euros) | 17 |
The following related company, which is part of Airbus Group, is taken into account: - Segula Matra Automotive.
4.5 FINANCIAL COMMITMENTS
4.5.1 COMMITMENTS GIVEN
Bpifrance repayable advance
A repayable advance totaling €14.507 million was received from Bpifrance, of which the final €1.451 million tranche was received in June 2019. The corresponding accrued interest amounted to €9.917 million at the end of the reporting period. This amount is repayable subject to achieving cumulative revenue of at least €38.000 million. The Bpifrance agreement provides for supplementary payments if certain conditions are met, so that the total amount repayable could exceed the amount of the advance initially granted, up to a ceiling of €50.000 million.
Royalties agreement with Professor Alain Carpentier and Matra Défense
On June 24, 2008, the Company signed a royalties agreement with Professor Alain Carpentier and Matra Défense, which was amended on February 5, 2010. Under this agreement, the Company has undertaken to pay to Professor Alain Carpentier and Matra Défense 2% of the net sales proceeds of the CARMAT artificial heart manufactured and distributed by CARMAT, with this amount to be divided between the two beneficiaries in proportion to their respective shares in the capital of the Company on the date it was established. These royalties will be payable every six months within 30 days of the end of each six-month period, commencing after the first marketing of the CARMAT artificial heart postCE marking in Europe and FDA marketing authorization in the United States, and ending upon expiration of the patents shown in the appendices to the agreement. The Company is also authorized to repurchase, at any time, the right to benefit from these royalties for a sum of €30,000,000, less any royalties already paid under the agreement, with this total sum being divided between the two beneficiaries in proportion to their respective shares in the share capital of the Company on the date it was established. This amount of €30,000,000 is indexed to the Producer Price Index of the Business Services Industry – euro zone orthopedic and orthopedic equipment. The rights allocated to Professor Alain Carpentier and to Matra Défense in this way are non-transferable.
Royalties agreement with the European Investment Bank (EIB)
In connection with the €30 million EIB loan granted to CARMAT in December 2018, the Company and the EIB signed a royalties agreement, amended on March 22, 2024, providing for the payment of additional compensation to the EIB depending on the commercial performance of the Company. The agreement covers sales generated by the Company until December 31, 2038.
The Company can decide to terminate the royalties agreement at any time by paying a lump sum (net of any royalties already paid), based on the amount borrowed and the year during which the decision is taken.
Upon the occurrence of certain events (in particular should the EIB demand the early repayment of the loan or should a new shareholder reach 33% of the voting rights of CARMAT), the EIB could, if deemed necessary, demand from the Company an advance payment of royalties up to a certain percentage of the amount of the loan effectively used (this percentage would range from 100% of the borrowed amount if the event occurs during the first four years of the financial agreement to 160% if the event occurs after the eleventh year). In addition, the Company must maintain a minimum cash position of €2 million at all times.
An amount of €48,302 due for first-half 2024 under this royalties agreement was recognized in the period.
Equitization agreement with the EIB: First call guarantee
Pursuant to the agreement concerning the equitization of the EIB loan (see the paragraph on the equitization process in Section 4.6.2), if the net proceeds from share sales are not sufficient to fully repay the first tranche of the loan to the EIB by July 31, 2026 (the new maturity date of the tranche), the Company would be required to repay the balance of this tranche due to the EIB in cash from its own cash resources at that date. Consequently, the Company has granted the EIB a standalone first-call guarantee in the event that the amount due under the first tranche of the EIB loan is not repaid on the date set in the EIB loan agreement.
4.5.2 COMMITMENTS RECEIVED
None.
4.6 OTHER INFORMATION
4.6.1 CASH FLOW STATEMENT
(in thousands of euros) | 6 months ended June 30, 2024 | 6 months ended June 30, 2023 | 12 months ended Dec. 31, 2023 |
NET OPERATING EXPENSE | (25,410) | (25,894) | (52,519) |
ELIMINATION OF INCOME AND EXPENSES WITH NO CASH IMPACT | |||
Depreciation/amortization and provisions | 12,115 | 8,046 | 14,551 |
Reversals of depreciation/amortization and provisions | (8,139) | (7,290) | (8,656) |
Gains or losses on disposals of assets | |||
Operating items with no cash or financial impact | 9 | ||
Operating items included in cash flow from (used in) financing activities | (349) | (1,028) | |
NON-OPERATING INCOME WITH AN IMPACT ON CASH OR CASH FLOW FROM OPERATIONS | 792 | (2) | 1,619 |
CASH FLOW FROM OPERATIONS BEFORE CHANGE IN WORKING CAPITAL | (20,992) | (25,130) (5,526) | (46,033) (7,446) |
CHANGE IN WORKING CAPITAL | (4,736) | ||
NET CASH USED IN OPERATING ACTIVITIES | (25,728) | (30,656) | (53,479) |
Acquisitions of property, plant and equipment and intangible assets | (1,268) | (1,590) | (5,026) |
Proceeds from disposals of property, plant and equipment and intangible assets | 3 | ||
Other changes in non-current assets | 146 | 110 | |
NET CASH FROM (USED IN) INVESTING ACTIVITIES | (1,119) | (1,590) | (4,915) |
Capital increase | 30 224 | 7 | 6,983 |
Increase in repayable advances | 1,318 | 2,318 | |
Repayment of repayable advances (including interest) | |||
New borrowings | |||
Repayment of bank loans and borrowings (including interest) | (368) | (771) | (1,100) |
Subscription of BSA share warrants | 90 | 110 | |
Subsidies received | 349 | 3,801 | 6,340 |
Financial income received and financial expenses paid | 6 | 198 | 315 |
Dividends paid | |||
Purchase/disposal of treasury shares | 43 | 22 | 15 |
NET CASH FROM (USED IN) FINANCING ACTIVITIES | 30,254 | 4,665 | 14,981 |
CHANGE IN CASH AND CASH EQUIVALENTS | 3,407 | (27,581) | (43,414) |
|
|
|
|
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 8,013 | 51,427 | 51,427 |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | 11,420 | 23,846 | 8,013 |
4.6.2 EQUITIZATION OF THE EIB LOAN
General information about the equitization operation
As part of the agreement entered into by CARMAT on March 22, 2024 with all of its lenders (including the EIB), the
Company and the EIB agreed – in particular in order to reduce the cash repayments due under the loan taken out by CARMAT with the EIB – to equitize the first tranche of the loan[19] so that it can be gradually converted into CARMAT shares via a management trust (the “Trust”) set up for the purposes of the equitization and managed by IQEQ, a trustee (the “Trustee”) that is independent of the Company and the EIB. The equitization will successively cover the three tranches of the loan, but the EIB may decide not to equitize the second and/or third tranches when the time comes, in which case the market will be informed accordingly.
In order to implement the equitization process, the Company will issue a number of share warrants free of consideration to the Trustee acting on behalf of the Trust. Each warrant entitles its holder to subscribe for one share in the Company. The Trustee will gradually exercise these warrants[20], then the shares issued on exercise of the warrants will be gradually sold by the Trustee on the market[21], and the net proceeds from the sales will be transferred by the Trust to the EIB every two months[22] until the sums due under the first tranche of the loan have been fully repaid to the EIB.
If the net proceeds of the share sales do not enable the first tranche to be repaid in full to the EIB by July 31, 2026 (the new maturity date of this tranche), the Company would be required to repay the balance due to the EIB for this tranche in cash from its own cash resources on that date[23]. The Company therefore has the possibility of partially repaying in cash the amounts due to the EIB under the first tranche of the loan. Equitization of the first tranche of the loan
On June 13, 2024, the EIB transferred its principal and interest receivable under the first tranche of the EIB loan (i.e., a total of €15.1 million) to the assets of the Trust. For technical reasons, this receivable was immediately transferred by the Trust to CARMAT so that the Company could cancel it through the merger of rights as a result of the same entity being the lender and borrower. This transfer of the receivable to the Company did not give rise to a cash payment but to the creation of a vendor loan owed by the Company to the Trust (the "Vendor Loan").
Under the terms of the Trust agreement signed for the purposes of the equitization, on June 13, 2024, the Company issued, free of consideration and without shareholders' pre-emptive subscription rights, 6 million share warrants to the Trustee acting on behalf of the Trust[24], which were fully subscribed by the Trust. At June 30, 2024, 193,143 of these warrants had been exercised by the Trust.
Accounting impacts of the equitization operation
The amounts due under the first tranche of the EIB loan, which has been equitized, are shown (principal and accrued interest) on the liabilities side of the balance sheet, under "Sundry loans and borrowings" (and no longer under "Bank loans and borrowings"). These amounts correspond to the debt (principal and accrued interest, i.e., €15.1 million) owed by CARMAT to the EIB on the date that the EIB transferred its receivable to the Trust (i.e., June 13, 2024), plus the interest accrued since that date, less amounts repaid or to be repaid by the Trust to the EIB. At June 30, 2024, these amounts totaled €14.7 million.
The capital increases resulting from the exercise of the share warrants by the Trust are accounted for in the same way as all other capital increases. In particular, in application of the reference method (ANC recommendation 2018-01), share issuance costs are recorded in the balance sheet as a deduction from the share premium.
4.6.3 OTHER ADDITIONAL INFORMATION
4.6.3.1 Pension and retirement obligations
The Company has not signed a specific agreement on retirement obligations. These are therefore limited to the lump-sum payment due on retirement as provided for in the applicable collective bargaining agreement.
In application of the reference method 1 in ANC recommendation 2013-02, the provision for retirement benefit obligations was recognized at June 30, 2024.
The overall amount of the provision was €0.542 million at the reporting date.
4.6.3.2 Information on executives
4.6.3.2.1 Advances and loans to management
No loans or advances were made to executives of the Company during the period (disclosure required in accordance with Article R.123-197 of the French Commercial Code).
4.6.3.2.2 Management compensation
During the first half, no compensation was paid to the members of the Board of Directors in their capacity as directors (formerly known as “directors’ fees”).
Total compensation paid to the Chairman of the Board of Directors and the Chief Executive Officer was €0.265 million for the period and breaks down as follows:
Management compensation (in thousands of euros) | 6 months ended June 30, 2024 | 6 months ended June 30, 2023 |
Gross salaries | 263 | 289 |
Benefits in kind | 1 | 5 |
Bonuses | 0 | 334 |
Total compensation | 265 | 628 |
4.6.3.3 Increases and decreases in future tax liabilities
Description of temporary differences (in thousands of euros) | Value |
Tax loss carryforwards | 488,603 |
This amount comprises:
- the tax loss generated in fiscal years prior to 2023, amounting to €433.159 million; - the tax loss generated in 2023 in an amount of €55.445 million.
It does not include the tax loss recorded for the first half of 2024.
4.6.3.4 Headcount at the reporting date
Salaried staff | June 30, 2024 June 30, 2023 | |
Managers | 120 | 135 |
Supervisors and technicians | 37 | 38 |
Administrative employees | 5 | 4 |
Total | 162 177 | |
[1] Breaking down as €1.5 million from commercial implants, €1.7 million from the EFICAS clinical study in France, and €0.1 million from miscellaneous sales.
[2] See the press release published by the Company on July 5, 2024 about this equity financing.
[3] Including the €2.2 million received in early July 2024 in connection with the Vester Finance equity financing line.
[4] See Section 4.2.1 for the factors underlying the going concern principle used by the Board of Directors.
[5] See the press release on the agreement published by the Company on March 22, 2024.
[6] See the notes to the 2024 interim financial statements (Section 4.6.2) for details of the equitization process.
[7] AP-HP GHU Pitié Salpêtrière, Hôpital Européen Georges Pompidou, CHU de Rennes, CHU de Strasbourg, Hospices Civils de Lyon, CHRU de Lille, Hôpital Marie-Lannelongue, CHU de Montpellier, CHU de Nantes and CHU de Dijon.
[8] Germany, Italy, Poland, Switzerland, Israel, Slovenia, Saudi Arabia, Serbia, Croatia, Austria, Denmark, the Netherlands, the Czech Republic and Greece.
[9] The first cohort of seven patients was finalized in the second half of 2021.
[10] Please see Section 4.6.2 of this document for an explanation of the equitization process.
[11] Compared with the original repayment schedules.
[12] At June 30, 2024.
[13] ECLS = Extra-Corporal Life Support
[14] Please see Section 4.6.2 of this document for an explanation of the equitization process.
[15] Compared with the original repayment schedules.
[16] Including €2.2 million received in early July 2024 in connection with an equity financing line set up with Vester Finance involving up to 3.5 million shares (for further details, see the press release published by the Company on July 5, 2024).
[17] See Section 4.2.1 for the factors underlying the going concern principle used by the Board of Directors.
[18] See section 4.6.2
[19] The equitization concerns both the principal and interest on the loan, so that once a tranche has been equitized, the Company will have nothing further to disburse in relation to that tranche before its new maturity date (except in cases of default or early repayment, which remain unchanged).
[20] The warrants may only be exercised by offsetting receivables. The Company will not receive any funds on exercise of the warrants as their exercise price will be paid by offsetting the receivable that the Company owes to the Trustee in relation to the Vendor Loan.
[21] The terms and conditions governing the exercise of the warrants and the sale of the shares issued on their exercise, particularly regarding prices and volumes, are set out in the trust agreement. Each warrant entitles its holder to subscribe for one share in the Company at an exercise price equal to the lowest volume-weighted average daily price of the Company's shares observed over the trading days during which the Trust has not sold any CARMAT shares, out of the last fifteen consecutive trading days immediately preceding its exercise date. The warrants may be exercised for a period of four years from their issue date, it being specified that any unexercised warrants will become automatically null and void once the receivables to be equitized have been repaid in full to the EIB. The objective of the broker in charge of selling the shares is to sell a daily volume of shares not exceeding 12.5% of the daily traded volumes of CARMAT shares, and for the sale price to be as close as possible to the VWAP of CARMAT shares on the day of sale.
[22] As an exception, the first payment will be made on July 31, 2024, with subsequent payments made every two months thereafter.
[23] The Company has accordingly granted the EIB a standalone first-call guarantee in the event that the amount due under the first tranche is not repaid at the date set in the EIB loan agreement.
[24] Additional warrants may be issued at a later date by the Company to the Trustee, acting on behalf of the Trust, if the number of warrants originally issued is not sufficient to fully equitize the first tranche of the loan.